Belite Bio to Present Phase 3 DRAGON Study Results at Two Major Ophthalmology Conferences
Event summary
- Belite Bio will present Phase 3 DRAGON study results for Tinlarebant at SOG and APVRS conferences in late August 2026.
- Presentations will cover adolescent and adult Stargardt disease treatment outcomes.
- Key presenters include ophthalmology professors from Stanford, University of Sydney, and University of Lausanne.
- Tinlarebant targets vitamin A-based toxins in degenerative retinal diseases.
- Belite Bio's lead candidate has received multiple regulatory designations including Breakthrough Therapy and Orphan Drug status.
The big picture
Belite Bio's upcoming presentations mark a critical juncture in the development of Tinlarebant, a novel oral therapy for Stargardt disease. The Phase 3 DRAGON study results could position the company as a leader in treating this rare, inherited retinal condition. With multiple regulatory designations already secured, the data presented at these conferences will be closely watched by investors and potential partners in the ophthalmology space.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 results will support accelerated approval pathways in the US and other regions.
- Market Potential
- The commercial viability of Tinlarebant in the Stargardt disease market given its orphan drug status.
- Competitive Positioning
- How Belite Bio positions Tinlarebant against emerging therapies for geographic atrophy and other retinal diseases.
Related topics